SUBSCRIBE
SUBSCRIBE

SYGNIS Pharma AG Set to Build on 2008 Achievements to Create Further Growth in 2009

February 5, 2009 | 
1 min read
Heidelberg, January 14, 2009 – SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today provided an update on its preparations for the next trial with AX200 in acute stroke as well as highlighting the milestones achieved in 2008.
Events Europe
MORE ON THIS TOPIC
Pictured: Roche tower in Basel, Switzerland
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
February 24, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Social media networking. Network with members connected with each other. Group of people. Communication, teamwork, community, society. Abstract concept with wooden pieces on blue background.
FDA
Moderna’s Outright Flu Refusal Just the Latest Case of Crossed FDA Signals
February 13, 2026
 · 
6 min read
 · 
Heather McKenzie
Viral vector, gene therapy, DNA delivery. Virus inserting genetic material into a cell nucleus. Gene editing, therapeutic genes, engineering, genetic diseases, dna, CRISPR, biotechnology. Medicine 3D illustration
Gene therapy
In Vivo Is Having a Moment as Cell and Gene Therapy Sector Gathers in San Diego
February 11, 2026
 · 
4 min read
 · 
Heather McKenzie
Photo showing male and female server engineers working on laptop in data center
Job Trends
10 Companies Hiring IT Professionals Now
January 29, 2026
 · 
2 min read
 · 
Angela Gabriel